Hikma moves into Morocco with $111M deal

Jordan's Hikma Pharmaceuticals has made its first foray into Morocco with a $111 million deal for controlling interest in Promopharm, the country's 9th-largest drugmaker with 200 branded generics and in-licensed products. The company plans to introduce about 20 Hikma products into the market as well. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.